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Abstract Visceral leishmaniasis (VL), also known as
Kala-Azar, is a disseminated protozoal infection caused
principally by Leishmania donovani and Leishmania
infantum (known as Leishmania chagasi in South Amer-
ica). The therapeutic options for VL are diverse and depend
on different factors, such as the geographical area of the
infection, development of resistance to habitual treatments,
HIV co-infection, malnourishment and other concomitant
infections. This article provides an exhaustive review of the
literature regarding studies published on the treatment of
VL, and gives therapeutic recommendations stratified
according to their level of evidence, the species of Leish-
mania implicated and the geographical location of the
infection.
1 Introduction
Visceral leishmaniasis (VL), also known as Kala-Azar, is a
disseminated protozoal infection caused principally by
Leishmania donovani and Leishmania infantum (synonym
Leishmania chagasi in South America). Occasionally,
Leishmania tropica in the Middle East and Leishmania
amazonensis in South America can produce VL [1].
Leishmania spp. are transmitted through the bite of
female haematophageous sand flies from the genus Phle-
botomus in the Old World and Lutzomyia in the New
World. Depending on the transmission characteristics, two
types of VL have been described. The zoonotic form,
caused mainly by L. infantum, with dogs as the main res-
ervoir, occurs in the Mediterranean Basin, China, the
Middle East and South America. The anthroponotic form,
with human-to-human transmission without an animal
reservoir, caused mainly by L. donovani, is prevalent in
East Africa, Bangladesh, India and Nepal.
The worldwide prevalence of VL is estimated to be
12 million cases, with approximately 0.2 to 0.4 million
new VL cases each year. More than 90 % of global VL
cases occur in just six countries: India, Bangladesh, Sudan,
South Sudan, Brazil and Ethiopia [2]. Co-infection with
HIV and Leishmania has been reported in more than 35
countries. Initially, most of the cases were from south-
western Europe, but the number of cases is increasing in
Sub-Saharan Africa (particularly in Ethiopia), in Brazil and
in South Asia. Co-infection in India still seems not to be a
major problem and occurs in \2 % of VL patients [3].
Since the late 1940s, the traditional treatment for VL has
been the use of pentavalent antimonials. However, in the
1980s, conventional amphotericin B deoxycholate was
introduced, followed by lipid formulations of amphoteri-
cin B—mainly liposomal amphotericin B—with high effi-
cacy and low toxicity. Paromomycin was then incorporated
as a cheap and effective parenteral drug, which can be
easily administered as an intramuscular (IM) injection.
Later, miltefosine was developed as an oral drug option for
VL. Nonetheless, clear differences in the clinical efficacy
of these drugs have been observed and are based on several
factors, which must be taken into consideration in treat-
ment decisions, such as the geographical area of the
infection [4], development of resistance (a striking fact in
the case of pentavalent antimonials in India over the last
couple of decades [5, 6]), HIV–Leishmania co-infection,
malnourishment and other concomitant infections [6].
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These conditions all modify the best treatment option to
cure the patient, minimize the occurrence of resistance and
decrease the duration of hospitalization, thus reducing costs
[4].
The objectives of this article are to make an exhaustive
literature review of VL treatment; to analyze the method-
ology and the results of the reviewed studies; to give
treatment recommendations based on the leishmaniasis
presentation form, country of origin and Leishmania spe-
cies: and, finally, to stratify the strength of the recom-
mendations on the basis of the Infectious Diseases Society
of America (IDSA) grade classification.
2 Methods
At the Tropical Medicine Unit of Ramo´n y Cajal Hospital
in Madrid, Spain, the medical literature was searched,
using databases such as MEDLINE, EMBASE, the Web of
Science and the Cochrane Library database. No limits were
placed with respect to the date of publication. No language
restrictions were imposed. The chosen search terms were
‘visceral leishmaniasis’ AND ‘treatment’ OR ‘parenteral
treatment’ OR ‘oral treatment’ OR ‘azole drugs’ OR
‘miltefosine’ OR ‘pentavalent antimonials’ OR ‘ampho-
tericin B’ OR ‘liposomal amphotericin’ OR ‘pentamidine’
OR ‘paromomycin’ OR ‘combination therapy’. Other
search terms were ‘visceral leishmaniasis’ AND OR ‘HIV’,
‘L. infantum’ OR ‘L. donovani’ AND ‘treatment’.
Bibliographical references from the included studies
were also reviewed. The reference sections of primary
studies, narrative reviews and systematic reviews were
examined to search for additional primary studies that
might have been missed during the electronic search.
Initially, only clinical trials were selected, in order to
obtain data with the highest-grade evidence. In the absence
of good-quality evidence, a second review was conducted
in order to obtain cure-rate information. Later searches
included original articles where data on results and treat-
ment regimens were shown, such as large case series and
multicentre studies, and also case reports when relevant
results were reported.
For each of the selected articles, the data that were
collected and analysed were the methodology, treatment
regimens (doses and duration), cure rates (always using
the last cure rate reported after the longest period of
follow-up; when not specified, the intention-to-treat cure
rate is given; when data on the per-protocol cure rate is
known, this is also reported), the country where the
study was performed and the Leishmania species that
was isolated (when they could not be identified, either
those species mentioned by the authors as being most
common in the area where the study was performed, or
those based on data published by the World Health
Organization (WHO) [7] or in other epidemiological
studies [2] were used). Such data were summarized in
tables for each of the leishmaniasis forms of presentation
that were studied.
On the basis of the methodology and the results of the
studies, treatment recommendations were outlined for each
leishmaniasis presentation form, country of origin and
Leishmania species. The strength of such recommendations
was stratified on the basis of the IDSA grade classification
(Table 1). In this system, the letters A–E signify the
strength of the recommendation for or against a therapeutic
measure, and the roman numerals I–III indicate the quality
of evidence supporting the recommendation [8, 9]. The
strength of the recommendation was determined on the
basis of several factors such as the number of studies
performed, the methodology of the studies, the number of
patients included, whether or not the specific Leishmania
spp. was isolated, and the time of follow-up.
Table 1 Infectious Diseases






A Good evidence to support a recommendation for use
B Moderate evidence to support a recommendation for use
C Poor evidence to support a recommendation
D Moderate evidence to support a recommendation against use
E Good evidence to support a recommendation against use
Quality of evidence
I Evidence from one or more randomized clinical trials
II Evidence from one or more well designed clinical trials, without randomization; from
cohort or case-controlled analytic studies (preferably from [1 centre); from multiple
time series; or from dramatic results from uncontrolled experiments
III Evidence from opinions of respected authorities, based on clinical experience,
descriptive studies or reports from expert committees
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3 Treatment of Visceral Leishmaniasis
3.1 Monotherapy
Studies of monotherapy for visceral leishmaniasis are listed
in Table 2.
3.1.1 Oral Treatment
3.1.1.1 Allopurinol and Azole Drugs (Fluconazole, Keto-
conazole, Itraconazole) The experience in the treatment
of VL with allopurinol is scarce, out of date and has
yielded disparate results. It is based on series of cases
where allopurinol was used mainly as a rescue treatment in
combination with antimonials or azole drugs [10–12].
The efficacy of treatment with azole drugs (fluconazole,
ketoconazole, itraconazole) was based on uncontrolled
studies with discordant results [13, 14]. The occurrence of
nephrotoxicity due to the combination of allopurinol and
ketoconazole was rare, and this enabled them to be used
with good results in renal transplant patients [10, 15, 16].
In conclusion, there is little evidence to recommend the
use of azole drugs or allopurinol in the treatment of VL.
GRADE: CIII
3.1.1.2 Miltefosine Several clinical trials conducted
5–10 years ago showed good evidence of efficacy with
miltefosine in VL in adults in India. Regimens of
2.5 mg/kg/day for 28 days have led to cure rates of
94–97 % [17, 18]. Some studies have demonstrated that
shorter regimens can also be effective; however, those
results cannot be generalized, because of the small numbers
of cases included and the absence of severe cases in those
studies [19]. Similar results in children aged \12 years
have been published [20, 21], showing the same efficacy as
that of amphotericin B deoxycholate in both newly treated
and sodium stibogluconate-resistant patients [22]. There-
fore, miltefosine was proposed as a first-line drug for VL in
India, Nepal and Bangladesh.
However, a single-group trial performed in 2011 in
Bangladesh, which included both adults and children,
achieved cure rates of 85 % with the standard miltefosine
regimen [23]. Another non-comparative study performed in
2012 in 567 adults treated with miltefosine in India showed
a cure rate of 90.3 % at 6-month follow-up [24].
Initially, development of miltefosine-resistant parasites
was thought to be the reason for this decrease in the cure
rates. In fact, resistance to miltefosine has been shown to
be easily induced in vitro [25, 26]. However, two recent
studies performed in Nepal and India in patients with VL
treated with miltefosine showed similar in vitro miltefosine
susceptibility (using an in vitro promastigote assay) in
cured patients and in patients who relapsed [27, 28].
Moreover, in the Nepal study, the only significant risk
factor that was found to be associated with relapse was age
\12 years, probably due to differences in children’s
immune response, drug pharmacokinetics, and exposure to
antigens. Another relevant fact was that the relapse rates
were 10 % at 6-month follow-up and 20 % at 12-month
follow-up. Considering that most clinical trials report
6-month follow-up, these findings also highlight the need
for a longer follow-up period to establish a cure rate for
miltefosine [27].
A clinical trial performed in Ethiopia in immunocom-
petent patients reported a 75.6 % cure rate [29]. Reliable
data on the efficacy of miltefosine in VL in the Mediter-
ranean region and Latin America have not been published.
Recommendation
Miltefosine regimen Grade
Miltefosine (orally) for 28 days:
2.5 mg/kg/day in
children aged 2–11 years;
50 mg/day in those aged
C12 years with bodyweight
\25 kg; 100 mg/day in
those aged C12 years with
bodyweight C25 kg;
150 mg/day in those aged
C12 years with bodyweight
[50 kg
AI: VL in the Indian
subcontinent, caused by
L. donovani
BI: VL in East Africa, caused by
L. donovani
CIII: VL in the Mediterranean
Basin and South America,
caused by L. infantum
3.1.2 Parenteral Treatment
3.1.2.1 Pentavalent Antimonials Sodium stibogluconate
(100 mg Sbv?/mL) and meglumine antimoniate (85 mg
Sbv?/mL) are the two available formulations containing
pentavalent antimonials.
They are currently considered the first-line drugs in
different parts of the world, except in those zones where
resistance has developed—fundamentally in the state of
Bihar (India), where the resistance rates are approaching
60 % of all cases [30].
The doses and durations of treatment regimens with
antimonials have undergone constant changes over the
years. Sodium stibogluconate was introduced in the late
1940s, becoming the first-line treatment for VL. It was
initially administered at low doses of 10 mg/kg/day for
6–10 days [31], but the occurrence of therapeutic failures
required progressive increases in the dose and duration of
treatment. In the 1980s, the first studies were done to
determine the most effective dose [32, 33] and, on the basis
of those studies, the WHO decided in 1982 that the daily
dose should be increased to 20 mg Sbv?/kg but specified



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Treatment of Visceral Leishmaniasis 1873
that the total daily dose should not exceed 850 mg [34].
The choice of this limit was exclusively based on the
quantity of Sbv? contained in two Glucantime vials (each
vial contains 5 mL with 85 mg Sbv?/mL) and on the fact
that patient bodyweight did not exceed 45 kg in the studies
that were initially reported [32]. Despite the fact that this
recommendation was for VL, it was also used for the
treatment of other clinical forms of leishmaniasis. How-
ever, some studies were published in which it was argued
that doses of greater than 850 mg Sbv? per day were more
effective [35]. Regarding the duration of the treatment, the
first studies increased the regimens to 20, 30 and 40 days
[32, 33]. Despite the fact that longer treatments (40 days)
had better response rates and fewer relapses, toxicity was
not taken into account. However, treatment regimens of
[28 days resulted in cardiotoxicity rates of 8–17 % [36].
Thus, in 1992, the final recommendation was parenteral
(IM or intravenous [IV]) administration of 20 mg Sbv?/kg
without a limit of 850 mg/day, for 28–30 days [37].
In Africa, the first trials were undertaken in Kenya in
1983 and marked a watershed in the determination of the
optimal dose of pentavalent antimonials [32]. However,
few new studies have been done since then. In the 1990s, a
comparative study was performed in Sudan between
sodium stibogluconate on its own versus sodium stibo-
gluconate combined with paromomycin, with response
rates that were higher with the combined treatment [38].
Other studies in Kenya and Sudan have analysed the effi-
cacy of generic sodium stibogluconate versus patented
versions, without observing any significant differences [39,
40]. Indeed, the generic formulae, which have a lower cost,
have allowed health authorities to administer the treatment
to more people in defined endemic zones in Africa, which
have low resources. In Uganda, a comparative study was
done between a cohort of patients treated with amphoteri-
cin B deoxycholate and a historic cohort of patients treated
with antimonials at a dose of 20 mg Sbv?/kg/day without
imposing a limit, with response rates of 95 % upon fin-
ishing the treatment [41]. A recent study conducted in
Ethiopia demonstrated differences in the cure rates after
6 months between patients from the North and those from
the South (80 versus 100 %), which was justified by the
different rates of HIV co-infection (46.4 % of the patients
from the North were HIV positive, while no HIV case was
detected among patients from the South). Thus, the efficacy
of antimonials in Ethiopia in immunocompetent patients
seems to be very high [42].
In the Mediterranean countries, VL is mainly produced
by L. infantum. In this case, the therapeutic evidence is
less solid, and within the same zone, therapeutic attitudes
even vary from country to country. During the 1990s,
antimonials were the first-line treatment in France,
Greece, Italy, Malta, Spain, Portugal, Morocco, Algeria
and Tunisia, with cure rates of 95 % in immunocompetent
patients [43]. However, the information collected from 11
countries in Southern Europe, Northern Africa and the
Middle East in the 21st century reflect certain variations
in treatment recommendations [44]. In Morocco, Tunisia,
Turkey and Palestine, antimonials at a dose of 20 mg
Sbv?/kg/day were the first-line treatment; in Portugal,
Spain, Greece and Italy, antimonials and amphotericin B
deoxycholate preparations were the two options for first-
line treatment (although antimonials were not adminis-
tered to patients with severe immunosuppression, and
preparations of liposomal amphotericin B were recom-
mended for treatment of relapses after antimonials); in
France, Italy and Cyprus, liposomal amphotericin B was
the first-line treatment, and relapses were treated with
different regimens of the same drug. A recently published
study collected a total of 1,210 cases of VL in children
aged 0–14 years in Albania from 1995 to 2009, and
demonstrated that antimonials at a dose of 20 mg Sbv?/
kg/day for 21–28 days continue to be effective, with a
cure rate of 99 % [45].
VL in the New World is produced by L. infantum/
chagasi. One of the most affected zones is the north-east
of Brazil, where 3,000–5,000 cases appear every year,
usually at a young age [46]. It is a zoonotic infection
resulting in a high percentage of asymptomatic patients,
in contrast to VL in India. Classically, the treatment of
VL in Brazil was based on the use of antimonials, with a
cure rate of up to 95 %, keeping amphotericin B
deoxycholate as a second-line treatment [47]. The recent
Pan-American Health Organization (PAHO) guidelines
for the treatment of leishmaniasis in the Americas has
established sodium stibogluconate as one of the first-line
treatments at a dose of 20 mg Sbv?/kg/day IM or IV for
30 days [48].
Recommendation
Pentavalent antimonial regimen Grade
Sodium stibogluconate
or meglumine antimoniate
(IM or IV) 20 mg Sbv?/kg/day
(upper limit 850 mg/day)
for 28–30 days
AI: VL in Bangladesh and Nepal
or in East Africa, caused by
L. donovani
AII: VL in children in the
Mediterranean Basin,
caused by L. infantum
BII: VL in the Middle East and
South America, caused by
L. infantum
EI: VL in India (except in
Jharkhand, West Bengal,
Uttar Pradesh states), caused
by L. donovani
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3.1.2.2 Amphotericin B Deoxycholate Amphotericin B
deoxycholate has been used for treatment of visceral and
mucocutaneous leishmaniasis in the New World [49, 50].
However, it was not until the beginning of the 1990s that
the first clinical trials were undertaken for the treatment of
VL in the Old World (India). These demonstrated response
rates of 98–100 % [50, 51] as first-line treatment, and 92 %
in those cases where antimonials had previously failed [51,
52]. In India, initially 99 % of all patients responded to
regimens of 1 mg/kg/day given daily or on alternate days
for up to 20 doses [53, 54]. Later, it was shown that it was
also effective (with a cure rate of 100 %) at lower doses of
0.5 mg/kg/day, given on alternate days for up to 14 days
[55].
Later studies demonstrated that daily administration was
equally tolerated and was as effective as administration on
alternate days [53, 56]. Because of the high rate of resis-
tance to antimonials in India, amphotericin B deoxycholate
seems to be established nowadays as the first-line
treatment.
However, in other geographical areas with low resis-
tance to antimonials, the use of amphotericin B deoxy-
cholate is not as widespread. In fact, in Europe, lipid
preparations of amphotericin B are used as first-line treat-
ment or in those cases where antimonials have previously
failed [44]. In Uganda, a cure rate of 92.4 % was obtained
with amphotericin B deoxycholate at a dose of 1 mg/kg on
alternate days for a period of 30 days, similar to the cure
rate in a historical cohort treated with antimonials and
without any difference in the occurrence of severe side
effects [41]. A retrospective study of five cases of VL in
Tunisia treated with amphotericin B deoxycholate at a dose
of 0.5–1 mg/kg/day for an average of 25 days obtained a
100 % response rate [57].
The PAHO guidelines for the treatment of leishmaniasis
in the Americas have established amphotericin B deoxy-
cholate (1 mg/kg/day IV up to an 800 mg total dose) as one
first-line drug [48].
3.1.2.3 Liposomal Amphotericin B In India, at least 10
different regimens of liposomal amphotericin B have been
tested and resulted in a diverse range of response rates [58,
59]. Administration regimens of 5 days with total doses of
3.75, 7.5 and 15 mg/kg have been tested, with response
rates that increase in proportion to the dose: 89, 93 and
96 %, respectively [60]. Regimens of a total dose of
20 mg/kg spread over 4 days have obtained a 98.8 % cure
rate [61]. However, another study found no differences
between different dosages of 2 mg/kg/day for 7, 5 and
3 days, obtaining a cure rate of 100 % [62]. There have
also been tests with different regimens of a single dose with
good results. One study compared a single dose of 5 mg/kg
versus administration over 5 days, with cure rates of 90 and
93 %, respectively [63]. Another study compared liposo-
mal amphotericin B in a single dose of 15 mg/kg versus
amphotericin B deoxycholate in a dose of 1 mg/kg/day for
20 days, with 100 % cure rates in both groups at the end of
treatment [59]. Likewise, other non-comparative studies
found that a single dose of 7.5 mg/kg achieved cure rates
of 96 % [64]. More recently, another study demonstrated
that a single dose of 10 mg/kg was as effective as the
conventional regimen of amphotericin B deoxycholate,
with response rates of 95.7 and 96.3 %, respectively [65].
There is very little experience of liposomal amphoteri-
cin B in Eastern Africa, and the recommendations are
based on results obtained in India. In Sudan, a total dose of
20 mg/kg was tested, with cure rates of 88 %, but a lower
dose of 12 mg/kg obtained only a 50 % response rate [66].
A later study, also performed in Sudan, supported the
previous results in which a relatively high total dose of
liposomal amphotericin B (15–49 mg/kg) was needed to
cure Sudanese patients [67]. However, in both studies,
most of the patients had high parasite density, had previ-
ously relapsed or suffered other severe underlying diseases
such as HIV or tuberculosis. A phase II clinical trial in
Kenya demonstrated efficacy of 20 % with total doses of
6 mg/kg, 90 % with total doses of 10 mg/kg and 100 %
with total doses of 14 mg/kg [68]. More recently, a case
was reported of a Kenyan immigrant in Australia who
travelled to visit friends and relatives and who responded to
liposomal amphotericin B at a total dose of 20 mg/kg over
5 days [69]. Currently, a randomized, multicentre, non-
inferiority clinical trial is being conducted in Eastern
Africa. It aims to compare a multiple-dose regimen with a
total dose of 21 mg/kg given as 3 mg/kg IV on days 1, 2, 3,
4, 5, 14 and 21, and expects to obtain 95 % efficacy with a
single-dose regimen. On the basis of the previous experi-
ence in India and Kenya [59, 64, 65], the trial will begin
with a 7.5 mg/kg single-dose regimen and, if this regimen
is found to be ineffective at the time of an interim analysis,
patients will be re-randomized to receive a higher dose (10,
12.5 mg/kg up to a maximum of 15 mg/kg) [70]. Thus, it is
expected that higher doses are needed in Eastern Africa
than in India.
In Southern Europe, doses of 3–5 mg/kg/day, up to a
total of 20 mg/kg in different regimens, have been dem-
onstrated to be effective in up to 99–100 % of patients
[71]. Total doses of 15, 18 and 24 mg/kg were tested in
Italy, with response rates of 91, 98 and 100 %, respectively
[72]. In Greece, one study administered a total dose of
20 mg/kg in a short regimen of 2 days, with a cure rate of
98 %, versus 90 % when it was administered over 5 days
[73]. Because of the large number of published case series,
there is an important accumulation of evidence regarding
the use of liposomal amphotericin B in pediatric popula-
tions in Europe, with response rates[97 % with total doses
Treatment of Visceral Leishmaniasis 1875
of 18–24 mg/kg in different regimens [74, 75]. It has been
shown that liposomal amphotericin B reduces the average
duration of hospitalization when compared with antimo-
nials [76] and that it was effective in those cases where
antimonials had previously failed [77] For all of these
reasons, and despite the absence of randomized clinical
trials, liposomal amphotericin B is considered a reference
treatment in the case of VL in the Mediterranean countries
in adults as well as in children [78].
In Latin America, there is much less evidence. In Brazil,
doses of 20 mg/kg have been proven to be effective [68]. In
Colombia, two cases were published, where treatment with
antimonials had failed, but both cases responded to lipo-
somal amphotericin B at a dose of 2 mg/kg/day for 21 days
in one patient, and a dose of 0.6 mg/kg/day for 15 days in
the other [79]. The PAHO guidelines for treatment of
leishmaniasis in the Americas have established liposomal
amphotericin B (3–5 mg/kg/day IV for 3–6 days, with a
total dose of 20 mg) as one of the first-line therapeutic
options [48].
3.1.2.4 Other Lipid Preparations of Amphotericin B
There is little evidence about the other different lipid
preparations of amphotericin B deoxycholate. In India, the
efficacy of amphotericin B lipid complex was compared
with those of amphotericin B deoxycholate and liposomal
amphotericin B, without encountering any significant dif-
ferences [58].
Despite the efficacy of lipid preparations, especially
highlighted by liposomal amphotericin B, and their lower
toxicity than that of amphotericin B deoxycholate, they
have the disadvantage of high cost, which is particularly
important in low-income countries. However, some low-
income countries in the Indian subcontinent (Bangladesh,
Nepal) and in East Africa (Sudan, South Sudan, Ethiopia
and Kenya) would have access to reduced-price liposomal
amphotericin B (AmBisome) through the Gilead/WHO
AmBisome donation programme. An attempt has been
made to develop inexpensive lipid-containing amphoteri-
cin B deoxycholate by mixing it with commercially
available lipid emulsions. A commercial standardized
product of pre-formed amphotericin B lipid emulsion is
licensed for use in VL in India, after obtaining a cure rate
of 91.1 % with total doses of 9–15 mg/kg [80]. A sub-
sequent study comparing four different administration
regimens of a 15 mg/kg total dose of amphotericin B lipid
emulsion obtained not only good results in terms of the
safety of the drug, but also cure rates of 100 % in patients
who received a single dose of 15 mg/kg [81]. Thus,
administering amphotericin B lipid emulsion at a total dose
of 15 mg/kg IV over 4 h in a single dose or spreading it
over a daily dose of 5 mg/kg for three consecutive days is
very effective (100 %) for the treatment of VL in India,





(IV) 0.7–1 mg/kg/day, on
alternate days, for 15–20
doses
AI: VL in the Indian
subcontinent, caused by
L. donovani
BII: VL in East Africa, caused by
L. donovani
BIII: VL in the Mediterranean
Basin and Latin America,




10 mg/kg for 1 or 2 doses
AI: (regimen 1 or regimen 2): VL
in the Indian subcontinent,
caused by L. donovani
(Regimen 2) liposomal
amphotericin B (IV)
3–5 mg/kg/day for 3–5
doses (total dose 15 mg/kg)
AII: (regimen 3 in adults and
regimen 2 in children): VL
in the Mediterranean Basin,
caused by L. infantum
(Regimen 3) liposomal
amphotericin B (IV)
3–5 mg/kg/day for 3–10
doses (total dose
18–30 mg/kg)





3–5 mg/kg/day for 6–10
doses (total dose 30 mg/kg)
CIII: (regimen 3): VL in South
America, caused by
L. infantum
3.1.2.5 Pentamidine When India faced the need to find
alternatives to pentavalent antimonials, pentamidine was
tested in VL-endemic areas. In the 1980s, pentamidine at a
dose of 4 mg/kg three times weekly for 12–21 days had
obtained a cure rate of 93 % [82]. However, the response
rate started to decrease after the 1990s to about 70–80 % in
certain areas of India [83]. Later studies compared it with
other therapeutic options used in those areas, as is the case
with amphotericin B deoxycholate, demonstrating that
pentamidine was less effective [84]. Other studies revealed
that the response rate increased when pentamidine was
combined with antimonials or allopurinol [85, 86].
In Eastern Africa, pentamidine proved to be effective in
the treatment of patients in Sudan after pentavalent anti-
monials had previously failed [87].
There is little literature about use of pentamidine in the
Mediterranean area and Latin America.
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The decrease in its efficacy, its serious and sometimes
irreversible toxicity, and the availability of other thera-
peutic options have meant that use of pentamidine has
practically been abandoned over the last 4–5 years.
3.1.2.6 Paromomycin (Aminosidine) In the 1990s, dif-
ferent clinical trials were conducted, injecting paromomy-
cin either alone or in combination with pentavalent
antimonials as treatment for VL in India (Bihar) and in
Africa (Kenya and Sudan).
In the state of Bihar (India), a phase II study was
developed to evaluate the effectiveness and tolerability of
paromomycin compared with antimonials. The patients
treated with paromomycin achieved response rates of
77–97 %, compared with 66 % for antimonials. In addition
to this, paromomycin showed a lower incidence of side
effects, which included ototoxicity and renal toxicity. For
this reason, it was concluded from this study that paro-
momycin was an adequate second-line treatment in cases
resistant to antimonials [88]. These results led to the
development of a phase III trial in Bihar from 2003 to
2004, where paromomycin was not inferior to amphoteri-
cin B deoxycholate, with final cure rates of 94.6 versus
98.8 %, respectively [89]. Recently, a study comparing the
efficacy of paromomycin 15 mg (11 mg base)/kg/day for
14 days versus 21 days reported the efficacy to be inferior
at 14 days [90]. Finally, a phase IV study investigating the
safety and efficacy of paromomycin in 506 adult and child
patients attending six clinical centres in the state of Bihar
has been published. All patients were treated for 21 days
with paromomycin 11 mg base/kg/day IM. The cure rate
after 6 months was 94.2 %, with good tolerability. With
the exception of an increase in liver function test param-
eters, which decreased towards baseline over time, paro-
momycin had a reasonably safe profile, including
demonstrated safety and efficacy in paediatric patients and,
though with limited data, in pregnant women [91].
In Africa, the majority of studies performed have been
based on comparisons between paromomycin and antimo-
nials, or on a combination of both. In a study in Kenya, the
cure rate of paromomycin at a dose of 11 mg base/kg/day
(until obtaining a negative spleen puncture or until
achieving 20 consecutive days of treatment) was 54.4 %
[92]. Later studies carried out in Sudan revealed that the
addition of paromomycin to antimonials increased the cure
rate to 95–97 % [38, 93]. Furthermore, a study conducted
in Sudan, Kenya and Ethiopia compared the efficacy of
paromomycin as monotherapy at a dose of 15 mg (11 mg
base)/kg/day for 21 days, antimonials as monotherapy for
30 days or the combination of both for 17 days. An interim
analysis showed that paromomycin monotherapy had effi-
cacy of \50 % 6 months after the end of treatment in
Sudan. This treatment arm was discontinued, and the trial
continued with a higher dose of paromomycin 20 mg/kg/
day for 21 days. After 6 months, the overall response rates
were 92.2 % with sodium stibogluconate and 63.8 % with
paromomycin; however, the efficacy of paromomycin
varied substantially between geographical areas, with cure
rates of 14.3–46.7 % in Sudan, 80 % in Kenya and
75–96.6 % in Ethiopia [94]. Faced with this low response
in Sudan, a new comparative study was carried out with
higher doses of paromomycin, either increasing the dura-
tion of treatment from 21 to 28 days or increasing the daily
dose from 15 to 20 mg base. Both options proved to be
more effective than the usual regimen of 15 mg (11 mg
base)/kg/day for 21 days, with cure rates of 81 and 80 %
with 15 and 30 mg/kg/day, respectively [95].






or IV) 4 mg/kg/day on
alternate days or three times
weekly for 15–20 doses
DI: VL in the Indian
subcontinent, caused by
L. donovani
DIII: VL in East Africa, caused
by L. donovani; VL in the
Mediterranean Basin and




(IM) 15 mg (11 mg base)/
kg/day for 21 days




(IM) 15 mg (11 mg base)/
kg/day for 28 days or
20 mg (15 mg base)/kg/day
for 21 days
BI: (regimen 2): VL in East
Africa (Kenya and Ethiopia,




Combined therapy has the following objectives: shortening
the duration of treatment (which leads to fewer side effects
and improved adherence to the regimen), lowering the cost
of the treatment, stopping the development of resistance,
and encouraging a cure, especially in complicated cases
(Table 3).
In India, one of several published studies regarding
combined therapy was undertaken in patients who had not
responded to pentavalent antimonials. It demonstrated
favourable results in patients treated sequentially with
pentamidine and antimonials [86]. Another similar study
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also underlined the positive effect of the combination of
pentamidine and allopurinol [85]. Also, in India and in
patients never treated before, the combination of paromo-
mycin and antimonials administered in short regimens was
more effective than the conventional and longer regimens
of antimonials [96, 97]. A more recent study showed
slightly greater efficacy with combinations of liposomal
amphotericin B at 5 mg/kg/day in a single dose followed
by different regimens of oral miltefosine, compared with
liposomal amphotericin B at 5 mg/kg/day in a single dose
(96–98 versus 91 %) [98]. In a comparative study per-
formed in India, all drug combinations that were tested
(single-dose liposomal amphotericin B plus miltefosine for
7 days or paromomycin for 10 days or miltefosine plus
paromomycin for 10 days) were non-inferior to the stan-
dard treatment (amphotericin B deoxycholate for 30 days);
patients in the combination groups had fewer adverse
events than did those assigned to standard treatment [99].
Another recently published study, also carried out in India,
assessed the combination of one single dose of liposomal
amphotericin B 5 mg/kg and miltefosine 2.5 mg/kg/day
for 14 days, and found that the final intention-to-treat cure
rate was 91.9 %, whereas per protocol it was 97.6 % [100].
In Eastern Africa, specifically Sudan, two studies dem-
onstrated that paromomycin associated with antimonials
(sodium stibogluconate) increased the response rate in
comparison with sodium stibogluconate as monotherapy
[38, 93]. In Kenya, a non-randomized trial compared par-
omomycin and sodium stibogluconate as monotherapy
versus the combination of both, the latter being the most
effective option [92]. In a study performed in East Africa
(Sudan, Ethiopia, Kenya and Uganda) monotherapy with
paromomycin (20 mg/kg/day for 21 days) or with sodium
stibogluconate (20 mg/kg/day for 30 days) was compared
with combination therapy (paromomycin 15 mg/kg/day
and sodium stibogluconate 20 mg/kg/day for 17 days).
Combination therapy was a safe regimen and just as
effective (cure rate 91.4 %) as antimonials on their own
(cure rate 93.9 %), thus being a good option for treatment
in Eastern Africa [101].
A phase II, open-label, randomized, controlled clinical
trial has recently been completed in East Africa; however,
the results are yet to be published. The trial assessed
whether a short combination of sodium stibogluconate
(20 mg/kg/day IM or IV for 10 days) plus a single dose of
liposomal amphotericin B (10 mg/kg on day 1), or oral
miltefosine (2.5 mg/kg/day up to maximum of 150 mg for
10 days, starting on day 2) plus a single dose of liposomal
amphotericin B (10 mg/kg on day 1), or oral miltefosine
alone (2.5 mg oral up to maximum of 150 mg for 28 days)




amphotericin B (IV) 5 mg/kg
single dose ? miltefosine
(orally) for 7–14 days: 2.5
mg/kg/day in children aged
2–11 years; 50 mg/day in those
aged C12 years with
bodyweight \25 kg; 100 mg/day
in those aged C12 years
with bodyweight C25 kg;
150 mg/day in those aged
C12 years with bodyweight
C50 kg
AI: (regimen 1 or regimen
2 or regimen 3): VL in
the Indian subcontinent,
caused by L. donovani




amphotericin B (IV) 5 mg/kg
single dose ? paromomycin
(IM) 15 mg (11 mg base)/kg/day
for 10 days
(Regimen 3) miltefosine (orally)
for 10 days: as
above ? paromomycin (IM)




antimoniate (IM or IV) 20 mg
Sbv?/kg/day for 17 days
(without an upper limit of
850 mg/day) ? paromomycin
(IM) 15 mg (11 mg base)/kg/day
for 17 days
3.3 Therapy in HIV-Infected Patients
Atypical forms of presentation and frequent relapses have
been described in immunosuppressed patients. Immuno-
globulin deficits, autoimmune diseases, tumours, organ
transplants, or use of corticosteroids, methotrexate or
tumour necrosis factor inhibitors can cause immunosup-
pression. Co-infection with HIV hinders the therapeutic
response, causing relapses to be frequent, especially in
patients with CD? cell counts\200 cells/lL, progressively
reducing the pharmacological options after every relapse.
There have been few clinical trials regarding the efficacy
of treatment in patients co-infected with HIV, and the
majority have been carried out in Europe (infections pro-
duced by L. infantum). There are still many unanswered
questions as to which should be the drug of choice, and the
dose, duration, maintenance therapy, prophylaxis and effi-
cacy of combined therapies in co-infected patients (Table 4).
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3.3.1 Oral Treatment
3.3.1.1 Miltefosine Miltefosine has been used, but there
is limited published clinical information about its efficacy,
tolerability and safety in HIV patients. The optimal
duration of treatment for primary infection or for relaps-
ing cases has not been established. One of the few pub-
lished reports took place in Europe, where miltefosine
was used within the Compassionate Access Programme
for those HIV patients in whom previous treatment for
VL had failed. Although the initial cure rates were 64 %,
almost all of the patients relapsed [103]. In Ethiopia, a
randomized, non-blinded clinical trial was performed,
comparing oral miltefosine 100 mg/day for 28 days with
sodium stibogluconate 20 mg/kg/day for 30 days in a
high-prevalence HIV population. The authors concluded
that miltefosine was safer but less effective than sodium
stibogluconate in HIV-infected patients [29]. Another
publication has reported the use of miltefosine in the
management of four co-infected patients in Spain. They
were severely immunosuppressed patients whose previous
treatment for VL with amphotericin B deoxycholate or
meglumine antimoniate had failed. All of the patients
seemed to respond with symptomatic improvement, but
when treatment was discontinued, all of the patients
relapsed [104].
3.3.2 Parenteral Treatment
3.3.2.1 Pentavalent Antimonials Although the preva-
lence of HIV-VL co-infection seems to be progressively
increasing in India, with rates [2–5 % in some recent
studies [105, 106], clear data on cure rates with antimonials
in co-infected patients are not available. However, there are
factors that could limit the use of antimonials for VL in
HIV patients in India: firstly, the rate of resistance to
pentavalent antimonials is high in India (especially in
Bihar, observed in non HIV patients); and secondly,
treatment regimens frequently need to be longer in HIV
patients than in non-HIV patients, so this would probably
increase the toxicity rates seen with antimonials.
Pentavalent antimonials have been used in co-infected
patients at a dose of 20 mg Sbv?/kg/day for 28–30 days in
different European case series, with response rates between
33 and 82 % and frequent relapses [107]. In two clinical
European trials, which compared meglumine antimoniate
with amphotericin B deoxycholate and liposomal ampho-
tericin B, the response rates recorded for antimonials were
65.9 and 37 % [108, 109].
In African data from Ethiopia, poor cure rates were also
found, with only 43.5 % of HIV-positive patients being
cured at 6-month follow-up [110]. Better results were
observed in another two studies performed in Ethiopian
populations, with 65.2–78.6 % cure rates, but a higher
proportion of non-HIV-infected patients were included in
the analysis [29, 42].
3.3.2.2 Pentamidine Regimens There have been no
clinical trials with pentamidine, and experience is limited
to clinical cases where, on many occasions, a combination
with other drugs was used [111].
3.3.2.3 Amphotericin B, Amphotericin B Lipid Complex
and Liposomal Amphotericin B Regimens Although
amphotericin B deoxycholate is one of the first-line drugs
in the treatment of VL, there has been only one compara-
tive study in HIV-infected patients, which was carried out
in Europe (Spain, L. infantum). This study demonstrated
that at a dose of 0.7 mg/kg/day for 28 days (20 mg/kg total
dose), amphotericin B deoxycholate was equally as effec-
tive in the initial cure and prevention of relapses as anti-
monials (cure rate 62.6 %) [108].
A total dose of 30 mg/kg of amphotericin B lipid
complex proved to be slightly superior to a total dose of
15 mg/kg amphotericin B lipid complex and to antimonials
(20 mg Sbv?/kg/day for 28 days) in co-infected patients in
a multicentre, open-label, blinded, randomized trial con-
ducted in Europe (Spain. L. infantum). However, the
response rate did not exceed 42 % [109].
Two studies have been carried out with liposomal
amphotericin B. One was in Ethiopia with a cohort of
HIV-positive and -negative patients treated with liposo-
mal amphotericin B (total dose 30 mg/kg), with a cure
rate of 60 %. Relapses were treated with sodium stibo-
gluconate (20 mg/kg/day for 30 days), increasing the final
cure rate in co-infected patients to 83 %. However, 16 %
of these patients died as a direct result of the toxicity of
sodium stibogluconate, highlighting the excess of toxicity
in HIV-positive patients [112]. In India, another retro-
spective cohort study included recently diagnosed VL–
HIV co-infected patients starting liposomal amphoteri-
cin B treatment at total doses of 20–25 mg/kg over
4–15 days. Excellent tolerability was observed, and ini-
tially all patients responded to the treatment, with final
cure rate of 85 % after 1–2 years post-treatment. [113]. It
is known that relapses can be treated in a similar way, as
no resistance to amphotericin B deoxycholate has been
noted.


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(Regimen 1) miltefosine (orally)
100 mg day for 28 days




meglumine antimoniate (IM or
IV) 20 mg Sbv?/kg/day
(without an upper limit of
850 mg/day) for 28 days
BI: VL in the Mediterranean
Basin, caused by
L. infantum
CI: VL in East Africa
(Ethiopia), caused by
L. donovani
Amphotericin B, amphotericin B
lipid complex, liposomal
amphotericin B
Amphotericin B (IV) 0.7
mg/kg/day for 28 days
BI: VL–HIV in the
Mediterranean Basin,
caused by L. infantum
Amphotericin B lipid complex
(IV) total dose 30 mg/kg
CI: VL–HIV in the
Mediterranean Basin,
caused by L. infantum
Liposomal amphotericin B (IV)
total dose 20–30 mg/kg
BIII: VL–HIV in India and
Ethiopia, caused by
L. donovani
3.3.2.4 Paromomycin Regimens The efficacy of paro-
momycin has not been established, and it is considered to
be a drug that fairly easily develops resistance [5]. The
different trials that have proven its efficacy involved
combined therapies with other drugs and were carried out
mainly in HIV-negative patients.
3.3.2.5 Combination Therapy There are no data regarding
the efficacy of combined therapy in HIV patients. None-
theless, many experts are in favour of combined therapy for
patients with multiple relapses [6]. Combinations of anti-
monials with other drugs such as allopurinol, ketoconazole,
fluconazole, itraconazole or interferon-c have been used, but
with insufficient evidence to consolidate the recommenda-
tion [114]. A case report from Italy described the safety and
efficacy of the combination of liposomal amphotericin B
(4 mg/kg/day for 5 consecutive days and on days 10, 14, 17,
31 and 38) and the growth factor recombinant human
granulocyte/monocyte colony-stimulating factor (rHuGM-
CSF) [150 lg subcutaneously twice weekly for 12 consec-
utive weeks] in an HIV-positive patient with VL. No side
effects were observed, and after 2 years of follow-up the
patient was still free from disease [115].
3.3.2.6 Maintenance Therapy The data regarding main-
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HIV-infected patients has fundamentally been developed
in Europe, where zoonotic transmission occurs by
L. infantum.
The only randomized clinical trial, which took place in
Spain, reported that use of amphotericin B lipid complex as
maintenance therapy administered at a dose of 3–5 mg/kg/
day IV every 3 weeks for 12 months, versus no treatment
at all, lowered the relapse rate from 50 to 22 % [116].
Another prospective study, also carried out in Spain, ana-
lyzed the efficacy of maintenance therapy with liposomal
amphotericin B at 4 mg/kg/day for 5 days and once weekly
for 5 more weeks (total 10 doses), achieving up to 80 %
patients being free of disease after 12 months of follow-up
[117].
Pentavalent antimonials were administered every
3–4 weeks as maintenance therapy in a study conducted in
Spain. The rate of relapses reduced much more signifi-
cantly than in those patients who either did not receive any
treatment or who took allopurinol for the 12 months of
follow-up [118].
Pentamidine was used at a dose of 4 mg/kg/day every
2–4 weeks in HIV-positive patients with VL caused by
L. infantum, without any evidence of relapses during the
follow-up period [119, 120].
Five cases reported in a study performed in Portugal
observed that the three patients who received miltefosine as
secondary prophylaxis for 21, 14 and 12 months, respec-
tively, remained disease free for a median period of
20 months. Miltefosine could be a good option for main-
tenance therapy until improvement of immune function
(CD4? cell count[250/mm3), because of its long half-life
and ease of oral administration. This could allow ambula-
tory treatment and even dose reductions, using an alternate-
day regimen [121].
Azole drugs could be effective in maintenance ther-
apy, although there are no clinical trials to support this
theory. The experience is based on series of cases where
itraconazole was given at a dose of 600 mg/day for up to
24 months of treatment, without any relapses. The
advantage of these drugs is their good tolerability and
low toxicity, although there is a risk of developing
resistant fungal infections [122, 123]. Itraconazole or
fluconazole combined with allopurinol could be an
option [124, 10].
Another relevant aspect to take into account is how long
maintenance therapy should be continued. According to
different authors, once the patient has recovered their
immune function with highly active antiretroviral therapy
(HAART) and the VL is quiescent, suspension of pro-
phylaxis could then be considered when the CD4? count
has been maintained at [200 cells/lL for more than
6 months [125, 126].
Recommendation*
Maintenance regimen Grade
(Regimen 1) amphotericin B lipid
complex (IV) 3–5 mg/kg/day
every 3 weeks
AI: (regimen 1): VL in the
Mediterranean Basin,
caused by L. infantum
(Regimen 2) meglumine
antimoniate (IM or IV) 850 mg
Sbv? in adults every 4 weeks
AII: (regimen 2): VL in the
Mediterranean Basin,
caused by L. infantum
(Regimen 3) pentamidine
isethionate (IV) 4 mg/kg/day
every 2–4 weeks
CIII: (regimen 3): VL in the
Mediterranean Basin,
caused by L. infantum
*Suspension of maintenance therapy could be considered after HA-
ART when the patient is stable and the CD4? has been maintained at
[200 cells/lL for [6 months
4 Conclusions
Currently, the control of VL relies primarily on chemo-
therapy. The traditional treatment for VL used to be pen-
tavalent antimonials, introduced in the late 1940s.
However, the development of resistance, especially in
India, with failure rates of up to 60 %, as well as their
potential toxicity, made it necessary to seek new treatment
options. Thus, since the 1980s, the use of amphotericin B
deoxycholate has been introduced, especially in more
developed countries. Progressively, and because of their
efficacy and lower toxicity, lipid formulations of ampho-
tericin have been gaining importance, becoming the first-
choice treatment established by the US Food and Drug
Administration (FDA). However, their elevated cost has
somewhat limited their use, but since the introduction of
the recent Gilead/WHO AmBisome donation programme
to Bangladesh, Nepal, Sudan, South Sudan, Ethiopia and
Kenya, this situation has improved. Several studies have
demonstrated the efficacy of paromomycin as a cheap
parenteral treatment with medium toxicity. Within the
range of oral treatments, miltefosine has been fundamen-
tally used on the Indian subcontinent. Combination therapy
will ultimately became the best drug regimen for treating
VL in many parts of the world.
Treatment of VL in HIV co-infected patients is less
effective than in HIV-negative patients, and relapses are
much more frequent. Within the available treatment
options, amphotericin B deoxycholate and particularly
lipid formulations seem to be the most effective. Mean-
while, it seems that standard treatment with antimonials
should be avoided because of their high toxicity in HIV-
positive patients. Another difficulty that is hard to manage
in co-infected patients is the frequent relapses. There is
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very little evidence regarding which drugs, doses and
durations to use for maintenance therapy. The common
relapses and prolonged secondary prophylaxis regimens
could favour the development of resistant strains, which
limit therapeutic options even further and create an epi-
demiological issue in areas of anthroponotic VL
transmission.
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